Acrux is a dynamic Australian specialty pharmaceutical company with vision and skills in transdermal drug delivery systems - ways of administering drugs through the skin - for many therapeutic uses.

Acrux Limited was established in 1998 to invest in specialty pharmaceutical businesses developing products which are intended to enable the safe and effective delivery of a broad range of drugs through the skin. The Company is a Pooled Development Fund (PDF)* that has three businesses that are currently developing a range of products.

Acrux's core business is the development and commercialisation of its transdermal drug delivery technology originally discovered at Monash University.

Drug treatments of potential interest to Acrux are selected for further development on the basis of the potential high value of the product and the sustainable advantage it would have in the market in terms of benefits to patients, physicians and payers (of healthcare).